System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maxime Breban is an expert in Rheumatology at Hôpital Ambroise-Paré (France). As of October 2026, ScienceLeadR ranks Maxime Breban in the top 1% of experts worldwide for Ankylosis, Axial Spondyloarthritis and Spondylarthritis. Maxime Breban has authored 305 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 3 of them ongoing. SLR score: 1,168 (community average: 125). How the SLR is computed.

LeadR Profile

Maxime Breban Hôpital Ambroise-Paré France
1 168 ScienceLeadR Reputation 1168

Unlock

Register Login
Network Map

Rheumatology

Subspecialties: Immunology - Public Health - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1991 - 2026
Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 305

Citations

Citations: 10 992 1st author: 35 Last author: 90 Unique author: 15

Main journals

Ann Rheum Dis 55
Revue du Rhumatisme 35
Joint Bone Spine 28
Arthritis Rheum 25
Rheumatology (Oxford) 14

Best Journals

JAMA 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Assessing the preclinical progress in the therapeutic targeting of axial spondyloarthritis.
PMID 42616835 — spondylitis, ankylosing, organoids, drug delivery systems, therapeutics, microbiota, axial spondyloarthritis		Expert Opin Ther Targets20260
Response of ultrasound-assessed synovitis to baricitinib, in monotherapy and combined with methotrexate, compared with etanercept in rheumatoid arthritis: a randomised, international, multicentre trial.
PMID 42025496 — arthritis, rheumatic diseases, arthritis, rheumatoid, etanercept, therapeutics, synovitis, methotrexate		Ann Rheum Dis20260
Contribution of intestinal mucosa to the disease mechanisms of Spondyloarthritis: Unlocking new insights through bioengineered tissue models.
PMID 41895459 — translational research, biomedical, intestinal mucosa, research, therapeutics, tissues, mucous membrane, autoimmunity		Autoimmun Rev20260
Dual JAK and IL-23 Blockade: A Mechanistically Supported Strategy in Refractory Psoriatic Arthritis.
PMID 41412314 — interleukin-23, arthritis, psoriatic, joint diseases, arthritis		Joint Bone Spine20250
Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trials.
PMID 41397742 — quality of life, safety, rheumatic diseases, drug-related side effects and adverse reactions, therapeutics, microbiota		BMJ Open20250

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4 Study Director: 1

By phase:

N/A 10
Phase 3 3
Phase 4 2
Phase 2/Phase 3 1

By status:

Completed 9
Recruiting 4
Unknown 2
Not yet recruiting 1

By type:

Interventional 11
Observational 5

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 0
multicentric5to9 1
multicentricup10 8

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
The Efficacy of Fecal Microbiota Transplatation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment
NCT05654753 — dysbiosis, fecal microbiota transplantation, spondylitis, ecosystem, capsules, spondylarthritis, therapeutics, transplantation, microbiota, axial spondyloarthritis		Phase 2/Phase 3Recruiting2024
The Role of Intestinal Microbiota Dysbiosis in the Development of Spondyloarthritis
NCT04853212 — ruminococcus, dysbiosis, spondylitis, biopsy, spondylarthritis, microbiota		N/ARecruiting2021
Efficacy of Non invasive Vagus Nerve Stimulation for Axial Spondyloarthritis Resistant to Biotherapies
NCT04286373 — vagus nerve stimulation, ear, external, cross-over studies, spondylitis, electrodes, ear, transcutaneous electric nerve stimulation, vagus nerve, spondylarthritis, therapeutics, biological therapy, axial spondyloarthritis		N/ANot yet recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS